Last reviewed · How we verify
Prothrombin Complex Concentrates
At a glance
| Generic name | Prothrombin Complex Concentrates |
|---|---|
| Also known as | Confidex |
| Sponsor | Angel Augusto Perez Calatayud |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
- Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients (NA)
- Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB) (PHASE3)
- Periinterventional Coagulation Management of Patients Undergoing a TIPS (NA)
- Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor (PHASE3)
- Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery (PHASE3)
- Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery (PHASE4)
- Coagulation in Cirrhosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prothrombin Complex Concentrates CI brief — competitive landscape report
- Prothrombin Complex Concentrates updates RSS · CI watch RSS
- Angel Augusto Perez Calatayud portfolio CI